Md Yusof MY, et al. - The clinical, interferon and imaging predictors of progression from “at risk” to autoimmune connective tissue diseases (AI-CTDs) were assessed. At risk of AI-CTD was defined as antinuclear antibody (ANA) positive, ≤1 clinical systemic lupus erythematosus (SLE) criterion, symptom duration <12 months, and treatment-naïve. Progression from ANA positivity to AI-CTD was predicted by a two-factor interferon score and family history. Individuals at risk of AI-CTD may be stratified by these interferon scores, thereby permitting early intervention for disease prevention and avoiding irreversible organ damage. In multivariable logistic regression, the odds of progression were increased only by family history of autoimmune rheumatic disease (OR 8.2) and IFN-Score-B (OR 3.79).